← Leaderboards
Cameron Amadeus Myhrvold
Rbhs-New Jersey Medical School
$892,721
Attributed
$1,931,399
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $791K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$1,931,399 · 2
By mechanism
R01$1,493,529 · 1
R21$437,870 · 1
Top collaborators
- Yingda Linda Xie4 shared
- Padmapriya Banada2 shared
Most similar at Rbhs-New Jersey Medical School
Same institution · by research overlap
- Thomas Dick$15,241,285
- Padmapriya Banada$145,957
Others in their field
Other Rising Stars on “Pathogen”
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Heinz Ernst Moser · University Of Texas Med Br Galveston$12,973,432
- Jason Dickens · Duke University$12,259,409
- Andrew Tomaras · Forge Therapeutics, Inc.$10,977,909
- John Alam · Eip Pharma, Inc.$10,411,018
- Anice Lowen · Emory University$10,193,979
Research focus
PathogenCostSputumSamplingValidationPrototypeEvaluationMycobacterium TuberculosisPerformanceResourcesTransmission ProcessTuberculosisTechnologyResearch PersonnelDetectionClustered Regularly Interspaced Short Palindromic RepeatsMortalityMorbidity - Disease RateFutureClinical ImplementationClinical DiagnosisAutomationCessation Of LifeCause Of Death
Grant awards (4)
Development of a highly-multiplexed CRISPR-based TB drug susceptibility test$702,499
R01 · FY2025 · AI
Development of a highly-multiplexed CRISPR-based TB drug susceptibility test$791,030
R01 · FY2024 · AI
Development of a rapid multiplex CRISPR-based testing pathway for tuberculosis and COVID-19$193,004
R21 · FY2023 · AI
Development of a rapid multiplex CRISPR-based testing pathway for tuberculosis and COVID-19$244,866
R21 · FY2022 · AI